{"id":"W2978840913","doi":"10.1016/j.molmet.2019.09.010","title":"Glucagon-like peptide 1 (GLP-1)","year":2019,"lang":"en","type":"review","venue":"Molecular Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1738,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"European Research Council; BERLIN-CHEMIE; Canadian Institutes of Health Research; Merck Sharp and Dohme; Medical Research Council; Johnson and Johnson; Servier; Novo Nordisk; National Institute for Health and Care Research; Novo Nordisk Fonden; Deutsche Forschungsgemeinschaft; Zafgen; Indiana University; Banting and Best Diabetes Centre, University of Toronto; Wellcome Trust; Alexander von Humboldt-Stiftung; Novartis Pharma; Helmholtz Association; Novartis; Merck KGaA; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Glucagon-like peptide-1; Glucagon-like peptide-2; Glucagon; Proglucagon; Incretin; Peptide; Chemistry; Internal medicine; Diabetes mellitus; Endocrinology; Medicine; Insulin; Biochemistry; Type 2 diabetes","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03531689130424301,"score_gpt":0.3185651192872342,"score_spread":0.2832482279829912,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}